Rituximab Biosimilars Market Report 2026

The rituximab biosimilars market size has grown rapidly in recent years. It will grow from $3.42 billion in 2025 to $3.84 billion in 2026 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to high cost of originator rituximab, increasing prevalence of non-hodgkin's lymphoma, growing incidence of chronic lymphocytic leukemia, rising awareness of autoimmune disease management, limited access to advanced biologics.

The rituximab biosimilars market size is expected to see rapid growth in the next few years. It will grow to $6.26 billion in 2030 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period can be attributed to launch of new biosimilar formulations, expansion of subcutaneous delivery options, increasing adoption in emerging markets, rising government and insurance support for biosimilars, integration with hospital and specialty pharmacy programs. Major trends in the forecast period include rising adoption of rituximab biosimilars for oncology and autoimmune diseases, expansion of subcutaneous administration and pre-filled delivery systems, growing preference for cost-effective monoclonal antibody alternatives, increasing use of antibody-drug conjugates (adcs) in targeted therapy, enhanced hospital and retail pharmacy distribution channels.

The increasing prevalence of non-Hodgkin's lymphoma (NHL) is anticipated to drive the expansion of the rituximab biosimilars market in the coming years. Non-Hodgkin's lymphoma is a form of cancer that originates in white blood cells, particularly lymphocytes, which play a key role in the immune system. The growing prevalence of non-Hodgkin's lymphoma is attributed to rising incidence rates, especially among aging populations, as well as lifestyle and environmental influences. Rituximab biosimilars effectively target and eliminate CD20-positive B cells, aiding in lowering tumor burden, improving immune system regulation, and offering a more affordable and accessible treatment option for patients with non-Hodgkin's lymphoma (NHL), thereby improving overall therapeutic results and quality of life. For example, in January 2024, according to the American Cancer Society, a US-based cancer advocacy organization, around 80,620 individuals (44,590 men and 36,030 women) were projected to be diagnosed with non-Hodgkin lymphoma, with approximately 20,140 deaths (11,780 men and 8,360 women), and the lifetime risk of developing this cancer was estimated at about 1 in 42 for men and 1 in 52 for women. Consequently, the growing prevalence of non-Hodgkin's lymphoma is contributing to the growth of the rituximab biosimilars market.

The increasing prevalence of autoimmune diseases is expected to support the growth of the rituximab biosimilars market in the years ahead. Autoimmune diseases are conditions in which the immune system mistakenly attacks healthy tissues, identifying them as foreign. Rituximab biosimilars are utilized in the management of autoimmune diseases by targeting specific B cells, thereby reducing inflammation and autoimmune activity. For example, in February 2024, according to Arthritis Australia, an Australia-based non-profit organization, an estimated 562,378 Australians were projected to be living with rheumatoid arthritis (RA) in 2025, representing 14% of all arthritis cases that year. By 2040, this figure is expected to increase by 33% to 748,721 individuals, reflecting an additional 186,343 Australians living with RA in 2040 compared to 2025. Therefore, the rising prevalence of autoimmune diseases is fueling the growth of the rituximab biosimilars market.

Leading companies operating in the rituximab biosimilars market are concentrating on the development of innovative products through strategic collaborations to improve accessibility and deliver more cost-effective treatment options for patients with a range of immunological and oncological disorders. Partnerships with established organizations enable companies to speed up commercialization, utilize shared expertise in regulatory approvals and distribution, and efficiently introduce biosimilars to the market, thereby enhancing patient access and market reach. For instance, in July 2023, Dr. Reddy's Laboratories partnered with Fresenius Kabi to commercialize its proposed rituximab biosimilar in the United States. This partnership is intended to introduce a biosimilar version of rituximab to the market, offering a more affordable and accessible treatment option for patients. The introduction of a biosimilar rituximab in the US has the potential to expand access to this critical therapy for patients with conditions such as rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis, and microscopic polyangiitis.

Major companies operating in the rituximab biosimilars market are Novartis AG, Pfizer, BIOCAD, Shanghai Henlius Biotech Inc., Innovent Biologics Inc., Cadila Pharmaceuticals, Hetero Drugs Limited, Dr. Reddy’s Laboratories, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Reliance Life Sciences India, Zenotech Laboratories, Celltrion, Biocad, MABION S.A., Amgen, Teva Pharmaceuticals, Celltrion Healthcare, Coherus BioSciences, Aryogen Biopharma, TR-Pharm, Hikma Pharmaceuticals plc.

North America was the largest region in the rituximab biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the rituximab biosimilars market report during the forecast period. The regions covered in the rituximab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rituximab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the rituximab biosimilars market by increasing the cost of imported biologics, raw materials, and infusion devices, affecting production and supply chain efficiency. Segments like intravenous infusion solutions and monoclonal antibodies are most affected, particularly in North America and Europe, which rely on imports for manufacturing and hospital use. Despite higher costs, tariffs have encouraged local production, accelerated biosimilar development, and promoted adoption of cost-effective treatment alternatives.

The rituximab biosimilars market research report is one of a series of new reports that provides rituximab biosimilars market statistics, including rituximab biosimilars industry global market size, regional shares, competitors with a rituximab biosimilars market share, detailed rituximab biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the rituximab biosimilars industry. This rituximab biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rituximab biosimilar is a chimeric monoclonal antibody designed to target the B cell-specific protein CD20 within the immune system. By eliminating B cells, it is effective in managing conditions characterized by excessive, overactive, or abnormal B cell activity.

Rituximab biosimilars are primarily administered through subcutaneous, intravenous, and molecular routes. Intravenous treatment involves the direct delivery of fluids, medications, or nutrients into a patient’s vein. These biosimilars are used in the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other indications, and are distributed via hospital pharmacies, online pharmacies, retail pharmacies, and other direct distribution channels.

The rituximab biosimilar market consists of sales of mabthera, truxima, ruxience, or rixathon. Values in this market are ''factory gate values,'' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.